In This Article:
-
Revenue: $33.7 million, a 5% sequential growth and 6% year-over-year increase.
-
Oncology Segment Revenue: Increased by $1.5 million or 9%.
-
Biomedical Services Revenue: Increased by over $0.5 million or almost 14%.
-
Equipment Rental and Disposable Medical Supplies: Increased by over $800,000 or almost 13%.
-
Pain Management Revenue: Grew by over $300,000, with a growth rate of more than 29% year-over-year.
-
Wound Care Revenue: Grew by over $300,000, with a growth rate of almost 190%.
-
Gross Profit: $16.7 million, a 5% increase from the prior year.
-
Gross Margin: 49.5%, adjusted to 51.1% after correcting a $600,000 travel accrual error.
-
SG&A Expenses: $14.8 million, a slight increase of over $200,000 from the prior year.
-
Adjusted EBITDA: $6.1 million, representing 18% of net revenue.
-
Operating Cash Flow: $2.3 million, increased by almost $2 million sequentially.
-
Net Capital Expenditures: $6.7 million, significantly higher than the prior year.
-
Net Debt: Increased by just under $4 million to $34 million.
-
Available Liquidity: $40.3 million at the end of the quarter.
Release Date: August 08, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
InfuSystems Holdings Inc (INFU) reported record net revenue of $33.7 million for the second quarter of 2024, marking a 5% sequential growth and a 6% increase over the prior year.
-
The oncology segment saw a revenue increase of $1.5 million or 9%, driven by higher treatment volumes and strong cash collection results.
-
Biomedical services revenue increased by over $0.5 million or almost 14%, benefiting from the full run rate of a large GE contract.
-
The company signed a new large customer for a three-year agreement, contributing to a 13% increase in equipment rental and disposable medical supplies revenue.
-
InfuSystems Holdings Inc (INFU) maintained strong liquidity with $40.3 million available at the end of the quarter, supported by a revolving line of credit and manageable debt service requirements.
Negative Points
-
There was a decrease in equipment sales by $300,000, attributed to the normal timing cadence for large orders.
-
Operating cash flow for the second quarter was $2.3 million, slightly below the prior year second quarter.
-
Net capital expenditures increased significantly to $6.7 million during the second quarter, which was higher than both the first quarter of 2024 and the second quarter of 2023.
-
The wound care segment experienced a revenue decrease due to fewer placements of negative pressure pumps compared to the previous year.
-
The company's net debt increased by just under $4 million to $34 million during the second quarter of 2024.